MedTrace Logo

The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer

NCT06287320 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-03-01

No results posted yet for this study

Summary

This study is a prospective cohort study to evaluate the peripheral blood lymphocyte subsets as predicative biomarkers reflecting the efficacy and toxicity in patients with locally advanced non-small cell lung cancer (NSCLC) received chemoradiotherapy (CRT) with or without immune checkpoint inhibitors (ICIs).

Conditions

  • Locally Advanced Non-small Cell Lung Cancer

Interventions

RADIATION

concurrent or sequential chemoradiotherapy

Thoracic radiation therapy(with the prescribed dose of 50-70 Gy), concurrently or sequentially combined with platinum-based doublet chemotherapy.

DRUG

Immunotherapy

anti-PD-1/anti-PD-L1 immune checkpoint inhibitors

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Nan Bi, MD · Chinese Academy of Medical Sciences and Peking Union Medical College

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2025-12-31
Completion
2026-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06287320 on ClinicalTrials.gov